高级检索

    有应用前景,但任重道远——评靶向CD3和CD123双特异性抗体flotetuzumab在复发/难治AML中的研究

    A Promising Application Prospect, but It Still Has a Long Way to Go: Review on the Study of the Bispecific Antibody Flotetuzumab Targeting CD3 and CD123 in Relapsed/Refractory AML

      摘要
      • HTML全文
      • 参考文献(4)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回